Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer

Shintaro Narita,Norihiko Tsuchiya,Teruaki Kumazawa,Shinya Maita,Kazuyuki Numakura,Takashi Obara,Hiroshi Tsuruta,Mitsuru Saito,Takamitsu Inoue,Yohei Horikawa,Shigeru Satoh,Hiroshi Nanjyo,Tomonori Habuchi

Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer

2012

Shintaro Narita
Norihiko Tsuchiya
Teruaki Kumazawa
Shinya Maita
Kazuyuki Numakura
Takashi Obara
Hiroshi Tsuruta
Mitsuru Saito
Takamitsu Inoue
Yohei Horikawa
Shigeru Satoh
Hiroshi Nanjyo
Tomonori Habuchi

Background To assess the outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with a high risk of localized prostate cancer (PCa).

Keywords:

Urology
Prostatectomy
Prostate-specific antigen
Prostate cancer
Estramustine
Neoadjuvant therapy
Survival rate
Blockade
Docetaxel
Medicine
Internal medicine
Oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations